Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 17
Treatment-assignment count: 0
Stratification count: 0
NSCLC · Monoclonal Antibody
RET fusion is flagged as manual review required because public trials show inclusion required evidence in 21 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 17
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 9
Common snippets: MET exon 14 skipping | EGFR Exon 19 deletion | KRAS G12C
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT02648724 | https://clinicaltrials.gov/study/NCT01761240 | https://clinicaltrials.gov/study/NCT04837716 | https://clinicaltrials.gov/study/NCT07272642 | https://clinicaltrials.gov/study/NCT04310007 | https://clinicaltrials.gov/study/NCT07416058 | https://clinicaltrials.gov/study/NCT03049618 | https://clinicaltrials.gov/study/NCT07674368 | https://clinicaltrials.gov/study/NCT07259226 | https://clinicaltrials.gov/study/NCT07393555 | https://clinicaltrials.gov/study/NCT07436858 | https://clinicaltrials.gov/study/NCT03958097 | https://clinicaltrials.gov/study/NCT05800015 | https://clinicaltrials.gov/study/NCT04507217 | https://clinicaltrials.gov/study/NCT06868836 | https://clinicaltrials.gov/study/NCT02908906 | https://clinicaltrials.gov/study/NCT04244552 | https://clinicaltrials.gov/study/NCT03554473 | https://clinicaltrials.gov/study/NCT05262985 | https://clinicaltrials.gov/study/NCT06792435 | https://clinicaltrials.gov/study/NCT05577715